Atenolol: Difference between revisions
| [unchecked revision] | [checked revision] |
MDElliottMD (talk | contribs) Create stub for Atenolol (linked from Category:Beta Blockers / Barbiturates / Sedative-Hypnotics Members section) |
MDElliottMD (talk | contribs) parser-claude: Atenolol MedTemplate refill, Top 300 stub upgrade |
||
| Line 1: | Line 1: | ||
{{MedTemplate | {{MedTemplate | ||
| generic = Atenolol | | generic = Atenolol | ||
| brand | | brand = Tenormin | ||
| classes = Beta blocker | | structure = | ||
| | | classes = [[:Category:Beta blockers|Beta blocker (cardioselective β1)]], [[:Category:Antihypertensives|Antihypertensive]] | ||
| uses = <vote slug="hypertension-use">Hypertension (FDA, though displaced from first-line by JNC8 and contemporary guidelines)</vote>, <vote slug="angina-pectoris-use">Angina pectoris (FDA)</vote>, <vote slug="post-mi-use">Post-myocardial-infarction secondary prevention (FDA)</vote>, <vote slug="atrial-fibrillation-rate-control-use">Atrial fibrillation rate control (off-label)</vote>, <vote slug="supraventricular-tachycardia-use">Supraventricular tachycardia (off-label)</vote> | |||
| starting_dose = 25-50 mg PO once daily; titrate to 100 mg/day | |||
| preparations = Tablets 25, 50, 100 mg | |||
| fda_max = 100-200 mg/day depending on indication | |||
| pill_id = | |||
| routes = Oral | |||
| onset = BP effect within hours; full effect over 1-2 weeks | |||
| duration = 24 hours (once-daily dosing supported by long elimination) | |||
| halflife = 6-9 hours (substantially longer in renal impairment due to renal elimination)<ref name="tenormin-label">FDA Prescribing Information, Tenormin (atenolol), AstraZeneca/various, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/018240s031lbl.pdf</ref> | |||
| bioavailability = ~50% (oral)<ref name="tenormin-label" /> | |||
| pregnancy = '''Documented fetal growth restriction with chronic exposure'''; avoid in pregnancy if alternative β-blockers are appropriate. The β-blocker most consistently associated with intrauterine growth concerns<ref name="tenormin-label" /> | |||
| legal = [[USLegal:Prescription only|Rx-only]] in US | |||
| mechanism = <vote slug="atenolol-mech-claim">Selective β1-adrenergic receptor antagonist with minimal β2 activity at therapeutic doses, giving lower bronchoconstriction risk than non-selective β-blockers. '''Hydrophilic''' (unlike lipophilic propranolol and metoprolol), so it has very limited CNS penetration, giving much less CNS adverse-effect burden (depression, fatigue, vivid dreams) but correspondingly less migraine prophylactic efficacy compared to lipophilic β-blockers. '''Renally eliminated''', so accumulates in renal impairment and requires dose adjustment by creatinine clearance.</vote> Contemporary hypertension guidelines (JNC8 and onward) have moved atenolol away from first-line antihypertensive use based on trial data showing inferior cardiovascular outcomes versus other antihypertensive classes, particularly in older patients<ref name="tenormin-label" />. | |||
}} | }} | ||
== References == | |||
<references /> | |||
[[Category:Beta blockers]] | |||
[[Category:Antihypertensives]] | |||
Latest revision as of 06:47, 23 May 2026
Atenolol
Tenormin
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
No effects listed yet. Be the first to suggest one.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Summary
Common uses
Hypertension (FDA, though displaced from first-line by JNC8 and contemporary guidelines)0, Angina pectoris (FDA)0, Post-myocardial-infarction secondary prevention (FDA)0, Atrial fibrillation rate control (off-label)0, Supraventricular tachycardia (off-label)0
Pharmacy
Starting dose
25-50 mg PO once daily; titrate to 100 mg/day
Preparations
Tablets 25, 50, 100 mg
US FDA Max
100-200 mg/day depending on indication
Pharmacology
Routes
Oral
Onset
BP effect within hours; full effect over 1-2 weeks
Duration
24 hours (once-daily dosing supported by long elimination)
Half-life
6-9 hours (substantially longer in renal impairment due to renal elimination)[1]
Bioavailability
~50% (oral)[1]
Pregnancy
Documented fetal growth restriction with chronic exposure; avoid in pregnancy if alternative β-blockers are appropriate. The β-blocker most consistently associated with intrauterine growth concerns[1]
Legal status
Rx-only in US
Purported mechanism
Selective β1-adrenergic receptor antagonist with minimal β2 activity at therapeutic doses, giving lower bronchoconstriction risk than non-selective β-blockers. Hydrophilic (unlike lipophilic propranolol and metoprolol), so it has very limited CNS penetration, giving much less CNS adverse-effect burden (depression, fatigue, vivid dreams) but correspondingly less migraine prophylactic efficacy compared to lipophilic β-blockers. Renally eliminated, so accumulates in renal impairment and requires dose adjustment by creatinine clearance.0 Contemporary hypertension guidelines (JNC8 and onward) have moved atenolol away from first-line antihypertensive use based on trial data showing inferior cardiovascular outcomes versus other antihypertensive classes, particularly in older patients[1].
References
- ↑ 1.0 1.1 1.2 1.3 FDA Prescribing Information, Tenormin (atenolol), AstraZeneca/various, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/018240s031lbl.pdf